Recent Posts

Saw this on UKVapers and was surprised I hadn't seen it here! (Possible I've just missed it among all the threads  )

E-Cigarette-Research.com - click on the Worldwide Survey further down the page


Today's the last day to fill it in, takes 5 mins and might be useful - Dr Farsalinos does great positive research into e-cigs, any help we can give is worthwhile.

Just got my SVD and evod clone from Fasttech (19 days from ordering). Awesome, but has anyone else found the ridges on the telescopic tube of the SVD quite sharp? I'm thinking of wrapping them in tape or something, feels like I could cut myself if I hold too tight!

Great, strong post on ECITA today, fight on!

Regulation by Press Release: Is this what Nanny is now reduced to?

Hi grizwald56, I have to say because your Strawberry Ice Cream (10mg) is the only juice I vape! Nothing else I've tried touches it for smoothness of flavour, it's just my all-day vape

Yesterday's news has startled a lot of us and given many to think about how they would survive if this regulation does come into force, and on the back of that I have a question:
When you first posted this guide you said you might post more recipes, and the one I'm really interested in (obvs) is Strawberry Ice Cream! Do you think you might share this wonderful recipe with us?

I will continue to buy mine from Vape Escape until I no longer can, but I'd love the ability to try to replicate the flavour (if I ever have to) just for peace of mind!

What do you think?

Cheers for reading,

Nick

I'm not sure when this Impact Assessment by MHRA came out but it is interesting. It's quite long so I've summarised some interesting points in case tl:dr...

"We are only interested in e-cigarettes that contain nicotine, and we have adopted the term Electronic Nicotine Delivery Systems (ENDS) to describe these particular products."

Here's the key fact for cynics:

"The UK market for unlicensed NCPs is expected to be worth around £100m in 2014. By comparison, the existing licensed NRT market was worth £110m in 2012"

But they are happy to say (in a begrudging, convoluted manner):

"28. While contaminants in ENDS have been identified, and the long term health effects of inhaling ENDS vapour are unknown, so far there is an
absence of evidence that shows that these problems create significant harm to health.
29. There is also uncertainty about the long term effects of nicotine consumption, although it is worth noting that any risk is likely to be very small
compared with smoking."

They discuss 4 options, from "Do nothing" to "Medicinalise everything" (favoured result...)

And here are the estimated costs to manufacturers/vendors (of Options 3/4 - medicinalisation):

"51. To abstract from this uncertainty and provide an illustration of potential costs, we have estimated the direct costs that would be borne by a single UK firm wishing to import an ENDS product from a non-EU source. Such an importer would have to acquire and maintain a Marketing Authorisation (MA), a Manufacturer’s/Importer’s Authorisation (MIA), and as part of the MA, satisfy requirements for on-going monitoring of product safety and effectiveness once the product is on the market (pharmacovigilance). Distributing ENDS in the UK would also require a Wholesale Dealer Licence."

 
                                                             One-off | Annual Recurring | Present Value | Annualised

Marketing Authorisation costs
Lower estimate                                        £215,000     £1,000         £222,000     £26,000
Upper estimate                                        £350,000     £1,000         £357,000     £41,000

Manufacturer's Import Authorisation costs
Lower estimate                                        £23,000       £39,000       £322,000     £37,000
Upper estimate                                        £23,000       £190,000     £1,467,000  £170,000

Wholesale Dealer Licence costs
Lower estimate                                        £4,000         £9,000         £70,000       £8,000
Upper estimate                                        £7,000         £43,000       £331,000     £38,000

Pharmacovigilance costs
Estimate                                                 £10,000       £16,000        £150,000     £17,000

TOTAL
Lower estimate                                        £252,000     £65,000        £747,000     £87,000
Upper estimate                                        £390,000     £249,000      £2,288,000  £266,000

[I'm not sure what Present Value refers to here? Anyone else?]

Conclusion:

"Putting the costs into context 
58. From a UK societal perspective, our estimated costs of compliance lack meaning unless they can be put into the context of the possible benefits
the policy might bring. The lack of direct evidence of the safety and efficacy of licensed versus non-licensed NCPs (discussed in previous sections of this IA) means that we can not estimate these benefits directly. However, we can calculate the number of additional successful smoking quit attempts a year that the proposed policy intervention would need to generate in order for the benefits to justify the costs. On the costs side, we have used our estimated annualised cost range of £87,000 to £266,000. On the benefits side, we have used the estimated value of the health benefits gained from a successful quit attempt. We reported this figure as £74,000 in paragraph 35.

59. The calculation reveals that very few additional successful quit attempts would be needed in order to justify the costs borne by a single UK
MA holder. Given the uncertainty of our estimates, we think that the precise result (between 1 and 3 additional successful quit attempts a year) is much less important than the orders of magnitude of our estimates. These suggest that the policy would only need to be marginally successful (generate very few additional successful quit attempts) for it to be justified.

60. However the reverse might also be true. The policy might only need to be marginally unsuccessful for it to be considered a costly failure. If the
design and implementation of the policy has the effect of reducing access to NCPs (particularly ENDS) then it is possible that the number of successful quit attempts could decline. If there were no substantial countervailing health gains from improvements in safety, the policy’s overall impact could be highly negative."


I'm not sure I quite understand this - the value of the health benefits of one person quitting is £74,000, so they want to put costs of up to £266,000 on the vendor/manufacturer? Surely these costs would otherwise be borne by the NHS or the individual, why should the vendor pay to benefit the consumer?

Ask and you shall receive........ (but don't ask me, I'm keeping all the provaris sent this year!)